INTERNATIONAL PATENT: PFIZER INC., ASTELLAS PHARMA INC. FILES APPLICATION FOR "COMBINATION OF TALAZOPARIB AND ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER"

GENEVA, April 18 -- PFIZER INC. (66 Hudson Boulevard EastNew York, New York 10001-2192), ASTELLAS PHARMA INC. (2-5-1, Nihonbashi-HonchoChuo-Ku, Tokyo 103-8411) filed a patent application (PCT/IB2025/060226) for "COMBINATION OF TALAZOPARIB AND ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER" on Oct 09, 2025. With publication no. WO/2026/078615, the details related to the patent application was published on Apr 16, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): CZIBERE, Akos Gabor (67 Aquavia RoadMedford, Massachusetts 02155), KENNEDY, Dana Ann (c/o Pfizer Inc...